INTERVIEWS

Dr. Carol Satler discusses the recent (Nov 2018) FDA approval of Gamifant® (emapalumab-lzsg), the first and only treatment indicated for primary hemophagocytic lymphohistiocytosis (HLH). Gamifant®is a product of Sobi, an international bio-pharmaceutical company dedicated to rare diseases.

CEO of Updox CRM, Michael Morgan discusses why healthcare providers have to offer consumers a choice beyond portals, why a secure SMS text solution better reaches patients where they are – on their mobile phones (without the need for an app), and how providers can stop playing phone tag and better engage patients with HIPAA-compliant texting for appointments, scheduling, treatment and more.

Dr. Shankar Musunuri, Ph.D., MBA, is Chairman of the Board, CEO and Co-founder of Ocugen, Inc., discusses the Company’s lead clinical candidate (OCU300) that is currently in Phase 3 for patients with ocular graft versus host disease (oGVHD) and is the first and only therapeutic with orphan drug designation for oGVHD, and the Company’s second lead candidate (OCU310) which is also in Phase 3 for patients with dry eye disease.

CEO of Neem Biotech, Dr. Graham Dixon discusses the presentations at the American Society for Microbiology (ASM) Conference on Biofilms and the North American Cystic Fibrosis (NACF) Conference on a new way to enhance antibiotic effectiveness by reducing biofilms and bacterial virulence more broadly for the development of novel antimicrobial treatments for infections in chronic wounds and chronic respiratory infections including cystic fibrosis.

To build awareness for what the holidays can be like for people with chronic diseases (like MS), Erin Boyt talked about the unique challenges the season can bring.

Erin is a 43-year-old woman who was diagnosed with MS at age 27; she is  heavily involved in the development of GatherMS in her local community (Atlanta, GA) and is passionate about patient education and resources; she volunteers at her local MS center to help support and inform other patients who are newly diagnosed.

Elizabeth Buckle discusses the interoperability questions healthcare organizations should ask before choosing a new EHR for 2019. Recently, Deloitte surveyed 624 primary care and specialty physicians on their attitudes toward EHRs and found that interoperability is their top concern with 62 percent of those surveyed saying they’d like their current system to be more interoperable.

Parkinsons Foundation Caregiver Summit : Returning guest John L. Lehr discusses the commitment and efforts of the Parkinson’s Foundation in advancing training of neurologists who specialize in Parkinson’s Disease (PD).  

Dr. Frederick Beddingfield, Founder, President and Chief Executive Officer of Sienna Biopharmaceuticals, a clinical-stage medical dermatology and aesthetics company, talks about the company’s focus on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Dr. Beddingfield tells a compelling story about Sienna and also discusses the clinical trials the company has underway.

Dr. Hugh McTavish, Company Founder, President, and CEO of IGF Oncology, a biotech company developing targeted anti-cancer drugs, talks about their lead drug IGF-MTX, that targets the deadly blood cancer MDS (Myelodysplastic syndromes), and is currently in clinical trials at the Mayo Clinic.

More than 9 Million people in the US suffer 6 or greater Herpes Simplex 1 and 2 (herpes labialis) outbreaks every year with no existing medications indicated for the prevention of additional occurrences.

In this interview, Dr. Hugh McTavish, Company Founder, President, and CEO of Squarex, LLC, a  clinical-stage pharmaceutical company, talks about the company developing a topical formulation for the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Virus 1 or Virus 2.